XML 25 R70.htm IDEA: XBRL DOCUMENT v2.4.0.8
License Agreements (Additional Information) (Detail) (USD $)
 0 Months Ended 1 Months Ended 12 Months Ended 0 Months Ended
Apr. 13, 2011
Mar. 30, 2013
Dec. 31, 2013
Dec. 31, 2012
Dec. 31, 2011
Dec. 31, 2013
Orexo [Member]
Mar. 31, 2013
Orexo [Member]
Dec. 31, 2013
M D Anderson Cancer Center [Member]
Jan. 13, 2014
Subsequent Event [Member]
Mills Pharmaceuticals LLC [Member]
License And Collaboration Agreements [Line Items]                  
Annual maintenance fee               $ 200,000  
Milestone payment for Phase 3               200,000  
Cash paid for acquisition of Abstral rights   10,000,000 15,143,000              
Remaining cash held of Abstral rights             5,000,000    
Estimated year of licensed patents expiration           2019      
Upfront cash payment                 2,000,000
One-time payment of share upon achievement of regulatory milestones 5,000,000               4,000,000
Contingent payment upon FDA approval                 $ 3,000,000